Biocon (BIOCON) Q1 26/27 earnings summary

Executive summary

• Strategic integration of biosimilars and generics businesses, along with the full integration of Biocon Biologics Limited (BBL) as a wholly owned subsidiary, has enhanced operational strength, global reach, and future growth prospects.

• North America remains the largest market, with recent launches and expanded manufacturing capacity in the US and Malaysia expected to drive performance, especially in biosimilars.

• Europe and emerging markets see expanded product offerings, commercial partnerships, and technology-transfer initiatives, supporting growth and patient access.

• Focus on improving margins, free cash flow, and ROCE, with early benefits seen in generics profitability.

• Consolidated revenue from operations for Q1 FY27 was Rs. 43,360 million, up from Rs. 39,419 million in Q1 FY26, reflecting strong growth across segments.

Financial highlights

• Q1 FY27 operating revenue grew 10% year-on-year to ₹4,336 Cr (Rs. 43,360 million), with biopharmaceuticals up 17% year-on-year and services down 16%.

• EBITDA reached INR 902 crore with a 21% margin; net profit before exceptionals was INR 145 crore, up 245% year-on-year.

• Reported net profit was INR 141 crore, up 355% year-on-year; consolidated EPS at Rs. 0.87 for Q1 FY27, up from Rs. 0.26 in Q1 FY26.

• Interest costs declined 23% year-on-year to INR 213 crore.

• R&D spend rose 17% year-on-year to ₹240 Cr, representing 7% of revenue (excluding Syngene).

Outlook and guidance

• Expectation of accelerated growth and profitability, with momentum building in the second half of FY27, especially in biosimilars.

• Services segment expects FY27 to be a transition year, with sustainable growth returning from FY28.

• Continued focus on cash generation, debt reduction, and improved return ratios.

• Final dividends recommended: Rs. 0.50 per share for Biocon Limited and Rs. 1.25 per share for Syngene, subject to shareholder approval.